By attending this program, attendees learned how to:
- Treat patients with lung cancer, melanoma, head and neck cancers, hematologic malignancies and genitourinary cancers with FDA-approved immunotherapies
- Interpret the most recent clinical data supporting the use of checkpoint inhibitors, CAR T therapies, cytokines, oncolytic viruses and vaccines
- Identify and manage immune-related adverse events
- Employ strategies to overcome operational and reimbursement barriers to incorporating immunotherapy into your practice
- Apply foundational knowledge for optimized clinical implementation of SITC’s Cancer Immunotherapy Guidelines
Attendees were able to connect with regional immunotherapy experts during these interactive in-person programs, in subsequent quarterly webinars and through a dedicated SITC CONNECT online community.